Share This

Topics Comments

Cheung Kong VODone Limited Shenzhen International Holdings Limited Jiangxi Copper Company Limited REXLot Holdings Limited China Overseas Land & Investment Limited Chong Hing Bank Limited Agricultural Bank of China Limited Chow Tai Fook Jewellery Group Limited Capital VC Limited iShares A50 Standard Chartered Bank of Communications Bank of China China LotSynergy Holdings Limited agribank Agri Airlines Appl AUD Auto A Shares Brokers CAD fertilizer producers China Lottery Supermarket China Banks Communication Consumer China Econ Electricity China Finance China IT Petro Real Est China Resource Steel coal Commodity Beauty Drugs Enviro EURO Lang Simon Ting WongSir Andy Xie Expo Gambling Garment gas GBD Gold Gold Jew Gold mine Harbour Highways HK Apparel REITs Rentals HK Banks ETF HK Housing Market Real Est HK HK Stock iBond Infra Insure IPO jewel Mach Build Mat New Energy NZD Oil Paper Rare Earths Real Estate Market Food RMB Rising RMB RMB Bonds Shipbuilding Shipping Sports Stock Trend Taiwan Dollar (TWD) Textile Top 500 USD US Econ Util Water Yang Liu's 10 Stocks YEN Diary media Central Bank Monetary Policy Education Construction Emerging markets Nuclear power BillGross Cement HK retail logistics Swiss franc Social Security Fund Law Ka-Chung capital flow Financial and political policy Railway film Korean Won Roubini Faber Mobius
Topics Last reply time Nickname Content
CANSINO BIOLOGICS INC. 2022-09-13T13:45 財經茄呢啡 康希諾生物「克威莎霧優」新冠肺炎疫苗可支持滅活及其他疫苗,作為第四針甚至第五針加強劑去應用。新疫苗在激發體液免疫及細胞免疫之外,亦實現誘導黏膜免疫,可調動肺部免疫體系,可進一步加強預防功能,因此有助日後用同一思路作更多產品開發。至於其開發的mRNA新冠疫苗產品,則已進入臨床二期階段,他形容進展非常順利。
CANSINO BIOLOGICS INC. 2022-09-13T13:45 財經茄呢啡 康希諾生物(6185)近期推出霧化吸入使用的5型腺病毒載體(Ad5-nCoV)預防新冠肺炎疫苗,最近獲內地藥監局納入緊急使用範圍。因疫情邁向流感化下,新疫苗可作加強劑使用。
CANSINO BIOLOGICS INC. 2020-09-03T10:40 財經茄呢啡 康希諾生物(6185)獲得中國首個新冠病毒疫苗專利,但消息指,康希諾與加拿大的疫苗三期臨床實驗合作,受到中國干預而終止。但中午宣布已與俄羅斯公司Petrovax簽訂合作協議,並收到俄羅斯衛生部關於新冠肺炎疫苗的三期臨床試驗申請批准。
CANSINO BIOLOGICS INC. 2020-07-24T10:14 財經茄呢啡 醫學期刊《刺針》(Lancet)文章提到,有兩款疫苗的初步測試結果正面,正進入最後階段測試,分別是中國康希諾生物公司與中國軍事醫學科學院生物工程研究所,以及英國牛津大學與藥廠阿斯利康製藥。
CANSINO BIOLOGICS INC. 2020-07-24T10:14 財經茄呢啡 路透報道,「2020中國抗病毒藥物創新大會」上,康希諾生物執行董事兼聯合創始人邱東旭透露,正於中國建新工廠,至2021年初每年可生產1億至2億劑新型肺炎病毒疫苗。
CANSINO BIOLOGICS INC. 2020-07-24T10:14 財經茄呢啡 康希諾生物(6185)正在俄羅斯、巴西、智利及沙特阿拉伯招募4萬名志願者,啟動其新型肺炎病毒實驗疫苗的三期試驗。
CANSINO BIOLOGICS INC. 2020-04-14T11:59 財經茄呢啡 世衛指,全球有70隻新冠病毒疫苗在測試,其中3隻疫苗測試領先,其中香港上市的康希諾生物(6185)與北京生物科技研究所共同研製的疫苗已進入第二階段,較其餘兩隻疫苗又領先。康希諾根據重組新冠病毒疫苗(腺病毒載體)(「Ad5-nCoV」)I期臨床試驗的初步安全數據,康希諾與軍事科學院軍事醫學研究院生物工程研究所計劃於近期在中國展開Ad5-nCoV的II期臨床試驗。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.